LCTX icon

Lineage Cell Therapeutics

105 hedge funds and large institutions have $52.1M invested in Lineage Cell Therapeutics in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 71 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

more funds holding in top 10

Funds holding in top 10:

more first-time investments, than exits

New positions opened: | Existing positions closed:

less funds holding

Funds holding:

less ownership

Funds ownership:

60% less capital invested

Capital invested by funds: $130M → $52.1M (-$78.3M)

75% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 71

Holders
105
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$20K
Puts
Net Calls
Net Calls Change

Top Buyers

1 +$333K
2 +$237K
3 +$105K
4
Deutsche Bank
Deutsche Bank
Germany
+$95.6K
5
JG
Jefferies Group
New York
+$77.5K

Top Sellers

1 -$3.91M
2 -$2.84M
3 -$1.09M
4
BlackRock
BlackRock
New York
-$727K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$424K
Name Holding Trade Value Shares
Change
Change in
Stake
51
$31K
52
$30K
53
$26K
54
$25K
55
$23K
56
$23K
57
$21K
58
$21K
59
$21K
60
$20K
61
$19K
62
$19K
63
$18K
64
$18K
65
$17K
66
$16K
67
$15K
68
$15K
69
$15K
70
$14K
71
$14K
72
$12K
73
$12K
74
$11K
75
$11K